Fig 2: Serum Nostrin concentrations in AKI patients.Serum concentrations of Nostrin (A and D) are shown in comparison to serum NGAL (B and E) and KIM-1 (C and F) in Controls versus AKI subjects (A-C) and in AKI stages 1–3 according to KDIGO 2012 (D-F). All biomarkers were significantly higher in AKI patients than in Controls and Nostrin and NGAL increased with increasing AKI severity according to KDIGO (data in mean +/-SD, *: p≤0.05).

Fig 3: Comparison of serum Nostrin, NGAL and KIM-1 in relation to death, need of kidney replacement therapy and recovery of kidney function.Serum levels of Nostrin (A-C), NGAL (D-F), and KIM-1 (G-I) were evaluated in relation to all primary endpoints (survival, KRT, ROKF). Serum Nostrin, measured at the time of AKI diagnosis was significantly higher in subjects that fulfilled the criteria of the three endpoints. Comparable observations were made for NGAL. KIM-1 however did not differ in any of the endpoint categories (data in mean +/-SD, *: p≤0.05).

Fig 4: Comparison of serum Nostrin, NGAL and KIM-1 in relation to AKI entities.Differences in serum Nostrin (A-C), NGAL (D-F), and KIM-1 (G-I) in one out of three predefined AKI entities (septic AKI, prerenal AKI, cardiorenal AKI) in comparison to all other types of AKI are shown, respectively. None of the three biomarkers differed in any of the analysis (data in mean +/-SD).